Introduction
Bloodstream infections are among the most serious and severe bacterial infections, with high mortality rates. The recent increase in antibiotic resistance among Gram-positive bacteria has changed the clinical scenario, making the treatment of these infections more difficult.
Infective endocarditis (IE), which is mainly caused by Grampositive bacteria, has become more difficult to treat after the emergence of antibiotic resistance in its main etiological agents (streptococci, staphylococci and enterococci). Infection by methicillin-resistant Staphylococcus aureus (MRSA) has spread in an epidemic way, especially in some areas of the world, such as Spain, where more than 25% of hospital-isolated strains are reported to be resistant to methicillin. 1 Moreover, the problem of methicillin resistance in S. aureus is nowadays no longer restricted to hospitalacquired infections following the emergence of communityacquired MRSA in the USA. 2 Also alarming is the development of intermediate-and high-level resistance to vancomycin in strains of S. aureus. 3, 4 Vancomycin resistance is common in many nosocomial settings, and now also viridans streptococci, once a leading cause of subacute IE, are increasingly acquiring resistance to penicillin and other b-lactam antibiotics. 5, 6 The treatment of IE has traditionally been based on consensus acquired during the years in which the majority of IE was due to penicillin-sensitive streptococci, and few randomized clinical studies have been conducted in the past. The appearance of S. aureus tricuspid valve endocarditis in intravenous drug users, again a relatively easy-to-treat condition in the absence of resistance to the very active anti-staphylococcal penicillins, has prompted a series of trials aimed at defining optimal treatment schedules. The appearance of Gram-positive resistant and multi-resistant microorganisms, together with the increasing number of patients with comorbidities, and of infection of prosthetic valves, has created new problems and the need for more evidence. Many questions remain unresolved: some, like the role of new antibiotics in the treatment of resistant infections, are new; others, like the optimal duration of treatment, the exact role of combination therapy with aminoglycosides and cell-wall active antibiotics, or the efficacy of glycopeptides in the treatment of IE are old but unresolved, in the absence of evidence from the literature. The role of traditional laboratory diagnostic techniques, like the determination of serum bactericidal activity and synergy tests, as well as the role of newer techniques like therapeutic drug monitoring of plasma levels of antibiotics widely used in the treatment of Gram-positive bloodstream infections, but with a narrow therapeutic window, or whose optimal dosage in critically ill patients is yet to be defined, are likewise uncertain and not supported by a great body of evidence.
The situation is also alarming in the setting of sepsis, one of the most common causes of death in the developed world 7 with an estimated annual mortality rate of 30-50 deaths per 100 000 population. 8 Therefore, the emergence of Gram-positive multiresistant bacteria potentially causing sepsis is of serious concern to public health. Again, there is an urgent need to acquire sound evidence on the optimal treatment of sepsis in the setting of antibiotic resistance, and to evaluate the role of new drugs. Finally, infections of vascular prostheses are severe infections involving vascular grafts, whose treatment is made extremely difficult by the need to remove the infected material, generally a life-sustaining implanted medical device, and for which very scarce evidence exist as to the optimal medical or surgical treatment. 9 While some authors invoke the use of long-term suppressive antibiotic therapy for the treatment of these conditions, 10 the introduction of new antibiotics active on resistant strains offers new treatment opportunities; however very few data are available on this issue.
Objective
The aim of this study was to review the literature on the optimal treatment of severe bloodstream infections (sepsis, endocarditis, and infections of vascular prostheses) caused by resistant Grampositive strains, with a special focus on studies on new antibiotics against Gram-positive resistant microorganisms and new presentation of Gram-positive infections.
Materials and methods

Controversial issues
A group of experts in the field of bloodstream infections was identified and enrolled in a faculty. The faculty was in charge of defining controversial issues, developing a search strategy, and reviewing the retrieved literature in order to obtain data on controversial issues and to draw recommendations based on the best available evidence. After discussion with the faculty members, the following controversial issues were defined:
Role of aminoglycosides and teicoplanin in the treatment of resistant Gram-positive bacterial endocarditis. Optimal duration of treatment of resistant Gram-positive bacterial endocarditis. Optimal use of the new antibiotics (quinupristin/dalfopristin, daptomycin, linezolid, tigecycline) in the treatment of bloodstream infections caused by resistant Gram-positive strains. Use of microbiological techniques (i.e., bactericidal serum testing and synergy testing) and of pharmacokinetic data (e.g., monitoring of plasma levels of antibiotics) in the treatment of difficult-to-treat Gram-positive bloodstream infections.
For each controversial issue, one or more structured new issues, in the form of a query, were created to obtain a series of unambiguous queries on the basis of which to create appropriate strings to optimize high quality literature searches. In other words, the strings were to be optimized to retrieve comparative studies on the topics of interest.
Firstly, the issues were divided in two distinct areas (therapeutic and diagnostic/laboratory monitoring).
For the therapeutic area, the following new queries were created:
1. In the treatment of infective endocarditis caused by Grampositive microorganisms, is combination therapy with an aminoglycoside plus another antibiotic more effective than monotherapy? 2. In the treatment of infective endocarditis caused by Grampositive microorganisms, is therapy with an aminoglycoside in a single daily dose more effective than therapy in three divided doses? 3. In the treatment of infective endocarditis caused by Grampositive microorganisms, is therapy with teicoplanin as effective, and associated with fewer adverse events, than therapy with vancomycin? 4. In the treatment of infective endocarditis caused by Gram- positive microorganisms, what is the optimal duration of treatment? 5. In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective? 6. In the treatment of sepsis caused by multi-resistant Grampositive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
7. In the treatment of infections of vascular prostheses caused by multi-resistant Gram-positive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
For the diagnostic/laboratory monitoring area the following new queries were created:
1. In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is monitoring of plasma levels of vancomycin, gentamicin, and teicoplanin effective in reducing adverse events and costs, and in increasing treatment efficacy? 2. In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is the use of serum bactericidal and synergy testing (along with traditional methods such as minimum inhibitory concentration (MIC) determination) effective in reducing adverse events and costs, and in increasing treatment efficacy?
Literature search and study selection
A series of inclusion criteria for the studies was then defined for each query: population studied, type of intervention, comparator or confrontation, type of outcome, and definition of the type of studies to be retrieved. In general it was decided to restrict the search to the adult population, to consider primary outcomes (such as cure or mortality), and to limit the search to randomized controlled studies or other comparative studies. Animal studies, as well as studies limited to pharmacokinetic/pharmacodynamic analysis, were excluded. No restrictions on year of publication or language were introduced. In some cases, however, the strategy was modified and made less restrictive because (as in the case of new antibiotics) very few randomized or comparative studies were obtained. As a rule, the use of MeSH terms was preferred; to delimit the search the 'limits' function of PubMed was used. For each query, different research strategies were tried, and the one considered more effective (maximum of high quality studies retrieved with minimum non-pertinent material) was eventually chosen. The research was mainly conducted on the PubMed (MEDLINE) database, and completed with hand searching of references of retrieved studies and of other material obtained from web sites of scientific societies such as the American Heart Association and the Infectious Diseases Society of America. For each retrieved study a schematic report, based on a pre-defined form, was created.
After this phase, the obtained results were discussed with the group members. As for some issues the number of high quality studies obtained was too scarce, it was agreed to conduct a new literature search aimed at obtaining case reports, and to include cases from personal series of the faculty members. Minimum requirements for cases to be included in the evaluation were completeness and quality of exposition. Retrieved single case reports or case series were summarized on a pre-defined form. Case reports were searched for queries 5 and 7 in the therapeutic area (use of new antibiotics in the treatment of endocarditis and infections of vascular prostheses) using a new, unrestricted research strategy, which included only the MeSH term or generic name of the drug. The case reports to be included in the final collection were chosen after reading titles and abstracts. For query 7 (infections of vascular prostheses), only one case reporting treatment with the new antibiotics was retrieved; it was therefore decided to retrieve case reports describing modalities of treatment of infected vascular prostheses.
Classification and evaluation of selected evidence
The quality of the studies was then assessed. The methodological quality of randomized controlled trials and of non-randomized studies was assessed with the CONSORT method and NewcastleOttawa Quality Assessment Scale, respectively, while for case reports and case series the quality was assessed on the basis of a structured checklist.
Finally, the studies and case series/reports retrieved for each query were analyzed to draw draft recommendations, with the strength of each statement defined according to the GRADE score of the studies retrieved for that issue. 11 The results and the draft were then re-discussed with the faculty, and afterwards in an enlarged group that included a panel of experts in the field; as a result, those queries for which there were insufficient data or nonconvincing evidence to draw a recommendation were eventually eliminated from the final recommendations. These recommendations were presented and voted for during a national conference in which physicians involved in the treatment of these conditions had convened.
The queries with the inclusion criteria, the search strings, and the flow charts with details of the results of the research for each query are presented in the Appendix. The results of each search, 
Note: the minimum score which can be assigned to each evidence is 1.
with the papers included and excluded for each query, the predefined forms for the collection of case reports, and a schematic form for each retrieved study and case report are available on request from the group coordinator. The quality evaluation of the evidence obtained from comparative studies according to the GRADE Working Group method is presented in For these four queries a single research was conducted, i.e., a single, generic string was used for the MEDLINE search and the results were then refined manually.
Comparative studies
Eight comparative studies were retrieved. In one study by Fortú n et al., 13 conducted on a small population of intravenous drug users, teicoplanin was compared to cloxacillin + gentamicin in right-sided endocarditis caused by methicillin-susceptible S. aureus (MSSA); the results in the teicoplanin arm (at a dosage of 10 mg/kg/12 h for the first 3 days, 6 mg/kg/12 h for the following 4 days, and then 7 mg/kg/24 h for 21 days) were significantly worse, with 7/8 (87.5%) cured in the cloxacillin + gentamicin group and only 2/6 (33%) in the teicoplanin group. In another study, again by Fortú n et al., 14 the efficacy and safety of a short course of a combination of a glycopeptide (vancomycin or teicoplanin) and gentamicin compared with a combination of cloxacillin and gentamicin in the treatment of right-sided endocarditis caused by S. aureus was assessed. The results in both glycopeptide arms were inferior with respect to the cloxacillin + gentamicin arm (11/ 11, 100% success in the cloxacillin/gentamicin arm, vs. 6/10, 60% success in the vancomycin arm and 7/10, 70% in the teicoplanin arm); there were, however, no differences between teicoplanin (at a dosage of 12 mg/kg/day) and vancomycin. Ribera et al. 15 
Therapeutic area -query 5
In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
Comparative studies
Two comparative studies were retrieved, both referring to a randomized controlled trial that compared daptomycin vs. standard therapy in the treatment of bacteremia and endocarditis caused by S. aureus. The aim of this study was to test the noninferiority of daptomycin as compared to standard treatment. In the study by Fowler et al., 21 235 adult patients with one or more blood cultures positive for S. aureus infection were enrolled.
Patients were randomly assigned to daptomycin, 6 mg/kg/day (+ gentamicin for the first 4 days in left-sided endocarditis) or standard therapy (vancomycin or anti-staphylococcal penicillin + -gentamicin for the first 4 days), in an unblinded fashion. The main outcome was the clinical success rate in each of the two treatment groups in the modified intention-to-treat population, assessed 42 days after the end of therapy. In the study population, 53/235 (22.5%) had infective endocarditis: of these, 9/28 (32%) in the daptomycin group and 9/25 (36%) in the standard treatment group were cured. Nineteen patients in the daptomycin group and 16 in the standard treatment group had right-sided endocarditis. The success rate for both groups was similar: 8/19 (42%) in the daptomycin group and 7/16 (43%) in the standard treatment group. Nine patients in the daptomycin group and nine in the standard treatment group had left-sided endocarditis. In this small subgroup, the failure rate was very high in both treatment arms: one patient in the daptomycin group (11%) and two in the standard treatment group (22%) were cured. Considering the entire population of patients (endocarditis plus bacteremia), daptomycin was associated with more microbiological failures, while standard treatment was associated with more failures due to adverse events, though the differences did not reach statistical significance. In the study by Rehm et al. 22 (a subset analysis of the Fowler study), patients with endocarditis caused by MRSA (13 in the daptomycin group and 10 in the standard treatment group) were analyzed in detail. Of the 13 patients with MRSA infective endocarditis in the daptomycin arm, 4/8 (50%) of those with right-sided endocarditis and 0/5 of those with left-sided endocarditis were cured; the same rates were obtained in the standard treatment arm, with 3/6 (50%) of those with right-sided endocarditis and 0/4 of those with left-sided endocarditis cured.
Case series
Falagas et al. 23 reported a series of 33 patients with 34 episodes of endocarditis treated with linezolid. Nineteen were male; the median age was 66 years (range 0.5-80 years); co-morbidities were present in the vast majority of cases (eight chronic renal failure, eight diabetes, six cancer, four treatment with steroids, one rheumatoid arthritis, one HIV infection). There were 27 episodes on native valves, and seven involved prosthetic valves. The isolates were vancomycin-intermediate S. aureus (VISA; 10 cases), MRSA (eight cases), vancomycin-resistant Enterococcus spp (VRE; eight cases), coagulase-negative staphylococci (CoNS; five cases), Enterococcus faecalis (two cases), and Streptococcus mitis and Corynebacterium striatum (one case each). Linezolid was administered for a median of 42 days, associated in one third of cases with other drugs (rifampin in five cases, gentamicin in four, fusidic acid in three, amikacin in one). Eight patients underwent surgery. The reported success rate was 63.6%, and the overall mortality 33%. Muñ oz et al. 24 reported a series of nine cases of infective endocarditis successfully treated with linezolid. They were six males and three females, aged 57-82 years, with serious comorbidities (one cancer, three transplants). Five patients had a prosthetic valve infection (three aortic, two mitral) and four a native valve infection (two aortic, one mitral, one tricuspid). The isolates were MSSA (four cases), MRSA (two cases), and E. faecalis, Streptococcus mutans, and C. striatum in one case each. Patients received linezolid 600 mg every 12 h for 2-4 weeks after failure of previous antibiotic regimens. Four underwent surgery. The reported success rate was 100%, with no deaths after a followup of 7-31 months. Falagas et al. 25 reported a series of 19 patients with endocarditis treated with daptomycin. Nine were male; the median age was 60.5 years (range 13-92 years); co-morbidities were present in two thirds of cases (three chronic renal failure, two diabetes, one cancer, two systemic lupus erithematosus (SLE), three bone marrow transplantation). There were 17 episodes on native valves and two on prosthetic valves. The isolates were MRSA (eight cases), MSSA (five cases), VRE (three cases), and CoNS, E. faecalis, and C. striatum in one case each. Daptomycin was administered for a median of 28 days, associated in one half of cases with other drugs (rifampin in three cases, gentamicin in three, minocycline and linezolid, one case each). Data on surgery were not reported. The reported success rate was 57.8% and the overall mortality 38.9%. Howden et al. 26 reported a series of patients with serious infections caused by MRSA with reduced susceptibility to vancomycin. Eight patients had infectious endocarditis. Median age was 72.5 years (range 66-80 years). The majority of patients had associated co-morbidities. Left-sided endocarditis was present in five patients (mitral valve in two and aortic valve in three; two were prosthetic aortic valves). The vancomycin MIC was 2 mg/ml for five isolates and 4 mg/ml for three isolates. Of these eight patients, seven were treated with linezolid, in different schemes, three of whom (42.8%) were cured.
Single case reports
Sgarabotto et al. 27 reported a case of successful treatment of an MRSA aortic valve endocarditis with the combination of vancomycin and quinupristin/dalfopristin. Arias et al. 28 adopted with success an unusual drug combination -daptomycin at 9 mg/ kg + ampicillin + gentamicin for 6 weeks -after the failure of daptomycin monotherapy at the usual dosage for a mitral valve infectious endocarditis caused by vancomycin-resistant Enterococcus faecium. The patient experienced mild dizziness, which was attributed to the prolonged exposure to the aminoglycoside, but no renal adverse events were reported. Cunha et al. 29 reported clinical success with high-dose (12 mg/ kg) daptomycin in a case of bacteremia and probable endocarditis caused by a vancomycin-tolerant E. faecalis. Cunha et al. 30 also
reported an unusual case of a patient with Job's syndrome and MRSA meningitis who had failed a regimen of vancomycin + ceftriaxone + ampicillin. A diagnosis of mitral valve endocarditis was eventually made and the patient was successfully treated with a combination of high dose daptomycin (12 mg/kg) and linezolid. No adverse events were reported after an 8-week course. Matsumura and Simor 31 reported clinical success in a case of aortic valve endocarditis caused by a vancomycin-resistant E. faecium strain. The patient had failed a 2-week course of quinupristin/dalfopristin but responded to an association of quinupristin/dalfopristin + doxycycline + rifampin for 8 weeks. In this case, serum bactericidal testing showed the absence of activity of single drugs, while synergy testing showed that the association was synergistic. Viale et al. 32 reported a case of successful treatment of MRSA mitral valve endocarditis with quinupristin/dalfopristin followed by oral linezolid. Zinkernagel et al. 33 36 reported clinical success with quinupristin/ dalfopristin in a patient with MRSA tricuspid valve endocarditis complicated by septic pulmonary emboli, after failing sequential treatment with teicoplanin-co-trimoxazole and linezolid associated to vancomycin-rifampin-co-trimoxazole. Liu et al. 37 reported a case of MRSA endocarditis of the tricuspid valve associated with the presence of a Hickman's catheter and defibrillator, in which treatment with daptomycin failed. The patient was successfully treated with linezolid/fusidic acid and then teicoplanin. In this case, the failure of daptomycin and the success of the combination regimen with linezolid was attributed to the appearance of pulmonary emboli during treatment with daptomycin. Tenover et al. 38 reported the development of daptomycin resistance in an S. aureus isolate with hetero-resistance to vancomycin, during treatment for left-sided endocarditis. In this case, cure was achieved with linezolid. Babcock et al. 39 described a case of VRE infection of the tricuspid (and perhaps aortic) valve successfully treated with linezolid after failure of quinupristin/ dalfopristin. The patient, a woman with Down syndrome and mental retardation, completed the 6-week course of treatment with oral linezolid. Sakoulas et al. 40 reported a case of mitral valve endocarditis failing to respond to daptomycin because of acquisition of resistance during treatment. The patient was infected with an MSSA strain, but failed a standard regimen with gentamicin/ nafcillin; a short course of treatment with vancomycin had also been administered before blood culture results. After switching to daptomycin, a progressive increase in the MIC (from 0.125 to 2 mg/ ml) was noted. The patient was eventually cured with surgery and a combination of nafcillin and gentamicin. Schwartz et al. 41 reported a case of failure of sequential antibiotics in a mitral valve endocarditis caused by a vancomycinresistant E. faecium. The patient was sequentially treated with linezolid, daptomycin 6 mg/kg, an association of daptomycin 8 mg/ kg + gentamicin + doxycycline, and quinupristin/dalfopristin (which was associated with a transient negativity of blood cultures). Synergy tests showed the absence of synergy for any antibiotic combination. Serum bactericidal test showed the absence of bactericidal or bacteriostatic activity while on daptomycin 8 mg/kg.
Huang et al. 42 described a patient who was admitted with fever and treated for MRSA bacteremia. A diagnosis of mitral valve endocarditis and septic thrombophlebitis was made 44 days after admission. The patient received several antibiotic courses (among which were vancomycin, teicoplanin, daptomycin, linezolid, and fusidic acid) without effect, and eventually died of a Candida sepsis. Several blood cultures were positive for MRSA, with the emergence of daptomycin resistance during treatment. Lemaire et al. 43 reported a case of MRSA infection of the aortic valve, unsuccessfully treated with several courses of antibiotics (vancomycin, gentamicin, rifampin, daptomycin, linezolid, quinupristin/dalfopristin, trimethoprim) who was eventually cured after aortic valve replacement. An increased MIC for daptomycin (from 1 to 8) during treatment was reported. Chow et al. 44 reported a case of superinfection caused by E. faecalis during treatment with quinupristin/dalfopristin of an MRSA endocarditis. Pistella et al. 45 reported a case of community-acquired MRSA sepsis with endocardial and cerebral metastatic seeding who developed coma with multiple cerebritis lesions under vancomycin plus amikacin therapy. The patient was eventually cured with the addition of linezolid to the initial antimicrobial regimen. Shah and Murillo 46 reported a case of C. striatum endocarditis that was treated successfully with daptomycin plus rifampin for 6 weeks following an unsuccessful attempt at vancomycin desensitization and failure of linezolid therapy.
Therapeutic area -query 6
In the treatment of sepsis caused by multi-resistant Grampositive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective? 53 reported the results of a case-control study on the use of quinupristin/dalfopristin in adult patients with bacteremia caused by vancomycin-resistant E. faecium (vancomycin MIC 8 mg/l, teicoplanin MIC 8 mg/l, in vitro resistance to all other appropriate agents, and quinupristin/dalfopristin MIC 2 mg/ l). All patients with vancomycin-resistant E. faecium bacteremia before the availability of quinupristin/dalfopristin (January 1991-December 1993) were considered the historical control cohort. The intervention group (20 patients) was treated with quinupristin/ dalfopristin administered intravenously at 7.5 mg/kg every 8 h. The 42 patients in the control group received other antibiotics according to standard of care (vancomycin, b-lactams, ciprofloxacin, aminoglycosides). The main considered outcomes were recurrent bacteremia and in-hospital mortality. Recurrent bacteremia was lower in the intervention group (5/20, 25%) than in the comparator group (21/42, 50%; p = not significant), but in-hospital mortality was similar (intervention group: 13/20, 65%; control group: 22/42, 52%). A summary of these studies is reported in Table 2 .
Therapeutic area -query 7
In the treatment of infections of vascular prostheses caused by multi-resistant Gram-positive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
Comparative studies
Only one comparative study was retrieved, on a subset of patients from the study by Fowler et al. on daptomycin, 54 already presented in the results of query 1. The subset was composed of 38 patients with intravascular devices comprising both removable and non-removable catheters and vascular prostheses (pacemaker/defibrillators, coronary stents, tunneled catheters, abdominal aortic synthetic grafts, inferior vena cava filter, transjugular intrahepatic portosystemic shunt, intra-aortic balloon pump). As a group, no differences were noted in the two arms; 8/17 (47%) patients in the daptomycin arm and 9/21 (43%) in the standard treatment arm were defined as clinical success. Overall success was higher when antibiotic therapy was associated with removal of the device. In the case of pacemakers/defibrillators, a clinical success was obtained in 3/5 cases when the device was removed, as compared to 0/6 cases when the device was left in place. The differences were less clear in the case of tunneled catheters (success in 4/8 following device removal and in 2/3 when the device was left in place). The numbers however were too small for definitive conclusions.
Diagnostic/laboratory monitoring area -query 1
In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is monitoring of plasma levels of vancomycin, gentamicin, and teicoplanin effective in reducing adverse events and costs, and in increasing treatment efficacy?
Comparative studies
Two comparative studies were retrieved. One study by Ferná ndez de Gatta et al. 55 evaluated the cost-effectiveness of vancomycin serum concentration monitoring in patients with hematological malignancies. In this randomized, unblinded clinical trial, patients with hematological malignancies and Grampositive infection requiring treatment with vancomycin were randomized to two groups; in one, treatment was modified according to therapeutic drug monitoring (TDM) of vancomycin with the active intervention of a clinical pharmacist, while in the other group TDM was not performed. Both clinical and economic outcomes were considered. A greater incidence of nephrotoxicity was observed in the group not receiving TDM. Logistic regression analysis confirmed that TDM independently reduced the incidence of nephrotoxicity in this patient population. On the basis of this reduced nephrotoxicity, an incremental cost of US$ 435 per case of nephrotoxicity prevented was found for vancomycin serum concentration monitoring. The procedure appeared to be costeffective. The study however did not classify patients according to type of infection (e.g., sepsis, endocarditis), so the results are not generalizable to the population of patients with endocarditis. In another study by Welty and Copa, 56 patients were randomized to receive or not vancomycin TDM. The study was supported by a TDM pharmacist. TDM of vancomycin was associated with fewer episodes of renal failure (7/61, 11.4% in the TDM arm vs. 24/55, 43.6% in the non-TDM arm), decreased length of therapy (11.1 AE 5.8 days vs. 13.4 AE 13.6 days), and possibly reduced length of stay (36.8 AE 30.4 days vs. 44.5 AE 51.4 days). Only two patients (both in the non-TDM group) had endocarditis, so results are not immediately generalizable to this subgroup of patients.
Diagnostic/laboratory monitoring area -query 2
In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is the use of serum bactericidal and synergy testing (along with traditional methods such as MIC determination) effective in reducing adverse events and costs, and in increasing treatment efficacy?
Comparative studies
No comparative studies were retrieved.
Single case reports
Matsumura and Simor 31 reported a case of VRE aortic valve endocarditis in which time-kill synergy studies and serum bactericidal testing were used to test an association of quinupristin/dalfopristin + doxycycline + rifampin. Serum bactericidal testing showed the absence of activity of single drugs, while synergy testing showed that the association was synergistic. The patient received this treatment for 8 weeks and the outcome was successful. Schwartz et al. 41 reported another case of endocarditis caused by a vancomycin-resistant E. faecium, in which serum bactericidal testing and synergy testing were used to guide treatment. After failure of various regimens, an association of daptomycin 8 mg/ kg + gentamicin + doxycycline was tried. Synergy tests showed the absence of synergy for any antibiotic combination, while serum bactericidal tests at a dilution of 1:2 showed the absence of bactericidal or bacteriostatic activity while on daptomycin 8 mg/kg.
From the evidence to the recommendations
After thorough revision of the retrieved studies, four queries were eliminated because of paucity of data: three from the therapeutic area (regarding the administration of aminoglycosides in single or fractioned doses, the optimal duration of treatment in IE, and the use of new antibiotics in the treatment of infections of vascular prostheses) and one from the diagnostic/laboratory monitoring area (on the use of serum bactericidal and synergy testing). Therefore, the following discussion is limited to the five queries for which comparative studies and other evidence allowed the drawing up of recommendations.
Therapeutic area 4.8.1. Query 1
In the treatment of infective endocarditis caused by Grampositive microorganisms, is combination therapy with an aminoglycoside plus another antibiotic more effective than monotherapy?
The use of gentamicin (or other aminoglycosides) in association with cell-wall active antibiotics has long been a mainstay of therapy for severe infections, and it is still recommended in the treatment of endocarditis due to E. faecalis, where the combination of ampicillin and gentamicin is synergistic. The use of combination therapy in infectious endocarditis caused by S. aureus and other Gram-positive microorganisms is, however, less well founded, and based more on theoretical considerations and animal experiments than clinical evidence. Moreover, aminoglycosides are potentially nephro-and ototoxic, and their use requires monitoring of plasma levels of antibiotics.
Few comparative studies have tried to assess whether combination therapy with aminoglycosides in the treatment of Gram-positive IE is better than single therapy. Abrams et al 16 (GRADE score 1) compared single vs. combination (i.e., with aminoglycoside) drug therapy of S. aureus endocarditis in intravenous drug users in a randomized, open trial. The considered outcomes were time to defervescence, bacteriological failure, congestive heart failure, surgery, and mortality. There were no differences in the two groups, and mortality was uniformly low. Ribera et al. 15 (GRADE score 2) compared the efficacy of cloxacillin alone with that of cloxacillin plus gentamicin for the 2-week treatment of right-sided S. aureus endocarditis in intravenous drug users in a randomized, open trial. Again, there were no differences in the two groups. In another randomized, open trial, Sexton et al. 19 (GRADE score 2) compared two antibiotic regimens (ceftriaxone alone for 4 weeks or ceftriaxone + gentamicin for 2 weeks) for the treatment of adults with penicillin-susceptible Streptococcus endocarditis. No differences in the microbiological success were found, while more patients in the combination therapy arm were cured with surgery. These three studies, all showing no advantage of combination therapy, are limited by their open design and by the paucity of data on randomization; moreover, they were mainly conducted on populations of patients with a low mortality risk, so generalization to other groups of patients is uncertain. More recently, Cosgrove et al. 20 (GRADE score 3) studied the clinical impact of initial low-dose gentamicin on renal function in a group of patients treated for S. aureus infective endocarditis or bacteremia. The patients were enrolled in a randomized, open trial comparing daptomycin and standard anti-staphylococcal therapy in the treatment of bloodstream infections caused by S. aureus. Patients in the standard treatment arm were treated with an association of an anti-staphylococcal antibiotic (either vancomycin or an anti-staphylococcal penicillin) and gentamicin, while patients in the daptomycin arm received gentamicin if they had left-sided endocarditis. The trial was not designed to assess the effect of gentamicin on renal dysfunction, and the effect of gentamicin on clinical outcome was not assessed. Nevertheless, the results of this study show that small initial doses of gentamicin are also significantly associated with a decrease in renal function. In summary, the limited available evidence shows that aminoglycosides are not useful in the treatment of Gram-positive infectious endocarditis in low-risk populations (i.e., drug addicts with tricuspid valve S. aureus endocarditis and patients with endocarditis caused by susceptible strains of Streptococcus). There is also evidence that even short courses of aminoglycosides in the treatment of S. aureus bloodstream infections are associated with renal toxicity.
Query 3
In the treatment of infective endocarditis caused by Grampositive microorganisms, is therapy with teicoplanin as effective, and associated with fewer adverse events, than therapy with vancomycin?
Few studies compared vancomycin and teicoplanin in the treatment of infectious endocarditis. Gilbert et al. 17 (GRADE score 3) published the results of a randomized, double-blind study comparing a higher teicoplanin dose, i.e., a 12-mg/kg loading dose followed by 6 mg/kg/day, with a standard dose of vancomycin of 30 mg/kg/day in the treatment of patients with documented bacteremia due to Gram-positive cocci. The patients in the teicoplanin arm received it at a dose of 6 mg/kg every 12 h for three doses and then 6 mg/kg alternating with placebo every 12 h. A small subset of patients had infectious endocarditis. The enrolment was interrupted because of a high failure rate in the teicoplanin arm. The interim analysis showed that the failure rate of teicoplanin in patients with left-sided endocarditis almost achieved statistical significance (p = 0.07), and the authors concluded that teicoplanin at this dosage is not effective in the treatment of left-sided endocarditis caused by Gram-positive microorganisms. Huang and Hsu 18 (GRADE score 2) studied 51 patients with MRSA endocarditis (only definite cases according to Duke's criteria) in a retrospective, comparative study directly comparing teicoplanin and vancomycin in the treatment of IE. No differences emerged between the two treatment groups. In the study by Fortú n et al. 14 (GRADE score 2), patients with right-sided S. aureus endocarditis were randomly assigned in an open way to three arms: cloxacillin plus gentamicin; vancomycin plus gentamicin; and teicoplanin (12 mg/kg, given every 24 h, with
Recommendations
In the treatment of native valve MSSA infectious endocarditis, there is no convincing evidence of the usefulness of a combination of gentamicin with either vancomycin or an antistaphylococcal penicillin, while there is evidence that this combination is associated with an increase in toxicity, especially in patients aged over 65 years. Gentamicin in this condition must therefore be used with caution (B). In the treatment of native valve IE caused by MRSA there is limited evidence on the utility of combination therapy (D). The use of combination therapy is still indicated in the treatment of prosthetic valve S. aureus endocarditis (D). a loading dose of 24 mg/kg given on the first day) plus gentamicin. The results in the group treated with teicoplanin and vancomycin were comparable, but results in both arms were inferior to the results in the cloxacillin arm. There is some additional evidence demonstrating the inferiority of glycopeptides in the treatment of endocarditis caused by susceptible strains of S. aureus. The same author 13 (GRADE score 2) compared teicoplanin at decreasing doses (10 mg/kg/12 h for the first 3 days, followed by 6 mg/kg/12 h for 4 days, and 7 mg/kg/24 h for 21 days) vs. cloxacillin plus gentamicin in intravenous drug users with right-sided S. aureus IE. The cure rate was only 33% in the teicoplanin group as opposed to 87.5% in the cloxacillin/gentamicin group.
In conclusion, in the treatment of Gram-positive infectious endocarditis there is limited evidence that teicoplanin is inferior to vancomycin in the treatment of left-sided IE caused by Grampositive microorganisms, while in right-sided endocarditis caused by MRSA, teicoplanin and vancomycin achieve similar results. It must be remembered, however, that both drugs are inferior with respect to anti-staphylococcal penicillins in the treatment of MSSA endocarditis.
Query 5
Only two randomized studies, both on daptomycin, were found, one by Fowler et al. 21 (GRADE score 2) and the other by Rehm et al. 22 (GRADE score 2). Both refer to a randomized controlled trial comparing daptomycin to standard therapy in the treatment of bacteremia and endocarditis caused by S. aureus. Daptomycin was used at a dose of 6 mg/kg. The overall success rate was reported to be around 43% in the treatment of right-sided infectious endocarditis, a rate comparable to standard treatment. Failures in the daptomycin group were more commonly secondary to microbiological failure, while those in the control group were more commonly secondary to toxicity (mainly renal toxicity). The success rate in the treatment of left-sided endocarditis was very low for both treatment arms. In the subgroup of patients with MRSA, the success rate was 50% for rightsided endocarditis and 0% for left-sided endocarditis. Surgical treatment is reported in 2/9 patients with left-sided endocarditis in the daptomycin group and 1/9 patients with left-sided endocarditis in the standard treatment group, but no additional data on the outcome are given. This study adopted a very strict definition of success, with failure of obtaining a blood culture at 42 days of followup considered as a clinical failure. No randomized studies were found addressing the role of quinupristin/dalfopristin, linezolid, and tigecycline in the treatment of infectious endocarditis.
A series of cases (single case reports and case series) describing the use of these antibiotics in the treatment of infective endocarditis caused by multi-resistant Gram-positive microorganisms were found.
Daptomycin
Falagas et al. 25 (GRADE score 1) reported a series of 19 patients with endocarditis treated with daptomycin. In five of them (26%) the cause was MSSA, while the remaining 14 cases were caused by multi-resistant or difficult-to-treat Gram-positive microorganisms (MRSA 8/19, 42%; VRE 4/19, 21%; CoNS, E. faecalis, C. striatum one case each). No growth was reported in one case. The left side of the heart was involved in 13 cases and the right side in four; also reported were infection of the aortic arch and of a pacemaker wire, while for one case no description of the involved valve was given. Data on surgery were not reported. The reported success rate was 57.8% and the overall mortality 38.9%. Eight out of 13 (61.5%) patients with left-sided IE were considered cured, as compared to 2/ 4 (50%) of those with right-sided IE. The relatively high success rate in left-sided endocarditis is in contrast with the results of the randomized controlled trial 21 in which the success rate in left-sided IE was close to zero, but the high risk of bias inherent to case reports must be considered, such as reporting bias (exclusion of failures from reporting) and incompleteness of reporting. For example, in the series published by Falagas, in the majority of cases an adequate follow-up was not reported, data crucial for the determination of the real outcome in patients with IE. In the randomized trial, on the other hand, the definition of cure was stringent, with failure to obtain a blood culture during follow-up considered as a clinical failure; this can partially account for the marked differences in the outcome of left-sided IE treated with daptomycin in the different types of studies. All patients but three were treated with the standard dose (6 mg/kg), and in six cases side effects were reported: elevation of creatine kinase in four cases, renal failure in one case, and eosinophilic pneumonia in one case. Of the single case reports, some reported a clinical success with daptomycin, alone or in combination with other antibiotics, in the treatment of infectious endocarditis, while other reported failure. Of nine reported single cases of treatment of IE with daptomycin, three 28, 29, 35 (GRADE score 1 for each) reported a clinical success. In two cases, daptomycin was used at a higher dosage (9 mg/kg and 12 mg/kg, respectively), and in combination with other antibiotics (ampicillin + gentamicin in one case, linezolid in the other). Of note, in one case, failure with daptomycin alone at the standard dose of 6 mg/kg was reported before the successful use of combination therapy with a higher dose of daptomycin. The mitral valve was involved in both cases; the offending organism was VRE in one case and MRSA in the other. In the third case 35 (GRADE score 1), successful treatment of left-sided endocarditis caused by community-acquired MRSA with the association daptomycin/rifampin and mitral repair was reported; data on follow-up were, however, lacking. Six reports described clinical failure of daptomycin in the treatment of IE 37, 38, [40] [41] [42] [43] (GRADE score 1 for each). All but one were left-sided IE. In one case of mitral valve endocarditis caused by VRE 40 daptomycin at a higher dose (8 mg/kg) in association with gentamicin and doxycycline was used. Four authors 38, 40, 42, 43 (GRADE score 1 each) reported a progressive increase in the MIC of daptomycin during treatment, associated with clinical failure. Patients were infected with S. aureus and had previously been treated with vancomycin, or the isolate was resistant to vancomycin. Finally, a quantity of unpublished data regarding the treatment of IE with daptomycin, mainly based on retrospective multicenter observational studies, has recently been presented at an international conference. The panel experts believe that the recommendations will probably be revised following the publication of these data.
In conclusion, in the treatment of right-sided S. aureus IE, daptomycin is not inferior to the standard treatment, and it is currently approved for this indication. The use of daptomycin to treat left-sided endocarditis, at least at the standard dose (6 mg/kg)
Recommendations
Teicoplanin can be considered equivalent to vancomycin in the treatment of right-sided endocarditis (D). In the treatment of left-sided endocarditis, teicoplanin was inferior to vancomycin when used at a loading dose of 6 mg/kg every 12 h for three doses and then 6 mg/kg/day. In the treatment of left-sided endocarditis the use of teicoplanin at higher dosages, though common, is not supported by clinical evidence (D). Both drugs are inferior to anti-staphylococcal penicillin when the strain of S. aureus is susceptible to methicillin (C).
and as a single antibiotic, awaits further evidence. In patients with S. aureus infection pretreated with vancomycin or harboring strains of S. aureus with hetero-resistance to vancomycin, loss of activity of daptomycin during treatment must be considered.
Linezolid
No randomized trials addressing the use of linezolid in the treatment of IE were retrieved. A number of cases describe the use of linezolid in this condition. Two case series (Falagas et al. 23 and
Muñ oz et al. 24 ) report 33 and nine cases, respectively. In the case series described by Falagas et al. 23 .1%). The reported success rate was 63.6% and the overall mortality 33%. As in many reports, data on prolonged follow-up are lacking in the series by Falagas, so these figures must be viewed with caution. Moreover, some of the patients reported to have been cured, died because of co-morbidities during follow-up. If the patients who died during follow-up and those classified as improved are considered as clinical failures, the overall success rate is 57.5%. Surprisingly, better results were obtained in patients with left-sided endocarditis (success rate 60.8%) than in those with right-sided endocarditis (success rate 50%), and also surprising is the high success rate (71.4%) reported in patients with prosthetic valve endocarditis. The impact of surgery on outcome could not be assessed from these data, however only a minority of patients (8/ 33, 24%) were treated with surgery. Muñ oz et al. 24 (GRADE score 1) reported nine cases of IE treated with linezolid for refractory disease or intolerance to other antibiotics, and in three cases as an oral consolidation treatment for outpatients. All nine patients were cured, with a reasonable length of follow-up. Seven patients had left-sided IE, and in four of them a prosthetic valve was involved. The involved agent was MSSA in four cases and MRSA in two; E. faecalis was isolated (in association with MRSA) in one case, while the remaining three cases were caused by S. mutans, C. striatum, and CoNS. Surgery was performed in four cases. In single case reports, linezolid has been used with variable success. In three cases [41] [42] [43] (GRADE score 1 for each) treatment with linezolid was associated with clinical failure. All were leftsided IE. In one case of mitral valve IE caused by MRSA 42 (GRADE score 1), linezolid was reported to be associated with negativity of blood cultures, though the patient died because of a Candida sepsis. Clinical success was reported in a further three cases 30, 37, 38 (GRADE score 1 for each); two were right-sided IE and one was leftsided IE; linezolid was used in combination with high dose daptomycin in one case 30 (GRADE score 1).
In conclusion, the use of linezolid in the treatment of IE is not supported by comparative studies; however in the 50 cases reported in the medical literature, linezolid appears to be associated with a reasonable success rate, around 50%. A selection bias must nonetheless be considered, as successful treatments are probably more likely to be published than treatment failures. In some cases 37, 45 (GRADE score 1 for each) successful treatment with linezolid after failure of other regimens was attributed to the presence of metastatic embolization in the lung and brain, respectively, while in another case complicated with cerebral embolization 46 (GRADE score 1), failure of treatment with linezolid was reported. Treatment with linezolid was associated with thrombocytopenia in about 30% of cases.
Quinupristin/dalfopristin
No clinical trials addressing the use of quinupristin/dalfopristin in infectious endocarditis have been reported in the literature, and also evidence from case reports is scarce. There have been reports of successful treatment with quinupristin/dalfopristin in cases of infectious endocarditis caused by MRSA, vancomycin-resistant E. faecium, and S. epidermidis, either right-or left-sided. In these successful cases, quinupristin/dalfopristin has been used either alone or in combination with other antibiotics (vancomycin; vancomycin + levofloxacin; doxycycline + rifampin). Some of these cases also underwent heart surgery. There have also been reports of failure of quinupristin/dalfopristin. The cumulative number of case reports is however very small and does not allow conclusions to be drawn.
Tigecycline
There is insufficient literature regarding the use of tigecycline in the treatment of infectious endocarditis.
Query 6
In the treatment of sepsis caused by multi-resistant Grampositive microorganisms, is therapy with quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
The literature on sepsis is somehow confusing, owing to the incorrect use of the terms bloodstream infection, sepsis, and bacteremia as synonyms. For the purpose of this study, we chose to limit the search to the MeSH term 'sepsis', but to use the term
Recommendations
Daptomycin has been shown to be non-inferior to the standard treatment in the treatment of right-sided Grampositive IE caused by MRSA (C) and can also be considered in the treatment of right-sided IE caused by other Gram-positive resistant strains (D)
In the treatment of left-sided IE, daptomycin alone at the dosage of 6 mg/kg may be used, but the evidence supporting its use is still scarce. The use of higher doses (up to 12 mg/kg) is a possible option. Association with other antibiotics must be considered on an individual basis (D)
Linezolid can be considered in selected cases for the treatment of IE caused by Gram-positive resistant microorganisms, either alone or in combination with other antibiotics (D). Linezolid can also be used as an oral agent after an initial phase of intravenous antibiotic therapy, but this indication needs further studies (D). Owing to its peculiar pharmacokinetic profile, linezolid can also be proposed in IE caused by Gram-positive resistant microorganisms associated with metastatic septic foci (e.g., meningitis, brain abscesses, and splenic and pulmonary emboli) (D).
Quinupristin/dalfopristin can be considered in selected cases in the treatment of resistant Gram-positive infectious endocarditis, especially when caused by vancomycin-resistant E. faecium, and preferably in combination with other antibiotics (D).
There is insufficient available evidence on the use of tigecycline in the treatment of IE.
'bloodstream infection' in the statements of the recommendations. The majority of comparative studies on the use of the new antibiotics in the treatment of sepsis [47] [48] [49] [50] [51] (GRADE scores 2, 2, 1, 1, and 3, respectively) have compared linezolid with the glycopeptides vancomycin and teicoplanin. Few differences between linezolid and comparators were noted in these studies, so that it can be stated that linezolid is at least comparable to glycopeptides in the treatment of sepsis caused by resistant Gram-positive microorganisms. Only one study 49 (GRADE score 1) showed linezolid to be superior to teicoplanin, whose dosage was, however, at the discretion of the investigator. The quality of the studies is generally poor except for one study with a double-blind, doubledummy design. One out of the six studies on linezolid 52 (GRADE score 2) was a comparative study of two different modalities of administration (continuous vs. intermittent) of the drug. There were no differences in the two arms. The limited evidence does not support continuous administration of linezolid in this condition.
In conclusion, the studies seem to show that linezolid activity is comparable to that of glycopeptides in the treatment of sepsis by Gram-positive microorganisms.
The only comparative study on quinupristin/dalfopristin 53 (GRADE score 2) did not show a difference with the comparator (standard treatment) in a population of patients with sepsis and severe underlying conditions. The quinupristin/dalfopristin arm had better microbiological responses, but the overall mortality was high in both groups.
No data on daptomycin and tigecycline were found.
4.9. Diagnostic/laboratory monitoring area 4.9.1. Query 1 In the treatment of infective endocarditis caused by multiresistant Gram-positive microorganisms, is monitoring of plasma levels of vancomycin, gentamicin, and teicoplanin effective in reducing adverse events and costs, and increasing treatment efficacy?
The evidence to answer this query is very scarce. Monitoring of plasma levels of drugs is useful when these are critical to obtain a therapeutic effect, or when the therapeutic levels of the drugs are close to the toxic concentrations. In the treatment of infectious endocarditis, the need to maintain adequate plasma levels of drugs also has a theoretical basis, given the difficulty of attaining adequate antibiotic concentrations in the vegetations. Many studies on pharmacokinetics and/or pharmacodynamics of antibiotics have been conducted in this field, but the analysis of this type of evidence is beyond the scope of this work. In clinical practice, monitoring of plasma levels of the antibiotics used for the treatment of infective endocarditis is limited to the monitoring of vancomycin, gentamicin and, less frequently, teicoplanin. Monitoring of plasma levels of drugs is costly, so the analysis was restricted to cost-effectiveness studies. Only two studies were retrieved, showing that monitoring of plasma levels of vancomycin can be cost-effective, and can be associated with fewer episodes of renal failure, decreased length of therapy, and possibly reduced length of stay. None of the studies, however, was conducted on populations with infective endocarditis.
In the study by Ferná ndez de Gatta et al. 55 (GRADE score 2) the study population was composed of immunocompromised febrile patients with hematological malignancies, assigned to vancomycin either because of fever resistant to antibiotic treatment (ceftazidime + amikacin) or because of strong suspicion of infection due to Gram-positive organism. The proportion of patients with infectious endocarditis is unknown. In the study by Welty and Copa
56
(GRADE score 1), only two patients (among the 116 studied) had infective endocarditis.
In conclusion, there is only indirect evidence of the clinical usefulness of therapeutic drug monitoring of antibiotics in the management of infective endocarditis, and the evidence is limited to the monitoring of vancomycin.
Recommendations
In the treatment of bloodstream infections caused by multiresistant Gram-positive microorganisms, linezolid may be used in selected cases (C). The use of continuous infusion of linezolid is currently being investigated, but it is not yet supported by the current evidence (C).
Quinupristin/dalfopristin can be considered in the treatment of selected cases of bloodstream infections caused by vancomycin-resistant E. faecium (C). There is insufficient evidence to support the use of tigecycline in the treatment of bloodstream infections.
Therapeutic drug monitoring of plasma levels of vancomycin in the management of infective endocarditis is useful and probably cost-effective (C). Trough levels of at least 15-20 mg/ ml should be obtained. There is a lack of published evidence regarding the use of TDM for teicoplanin. When using teicoplanin, a trough concentration of !20 mg/ml should be obtained (D). Monitoring of plasma levels of other antibiotics is supported only by animal or PK/PD studies and cannot therefore be generalized to all clinical situations (D). 
